Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension

被引:121
作者
Itoh, T
Nagaya, N
Ishibashi-Ueda, H
Kyotani, S
Oya, H
Sakamaki, F
Kimura, H
Nakanishi, N
机构
[1] Natl Cardiovasc Ctr, Res Inst, Dept Regenerat Med & Tissue Engn, Osaka 5658565, Japan
[2] Nara Med Univ, Dept Internal Med 2, Nara, Japan
[3] Natl Cardiovasc Ctr, Dept Internal Med, Osaka, Japan
[4] Natl Cardiovasc Ctr, Dept Pathol, Osaka, Japan
[5] Tokyo Saiseikai Cent Hosp, Dept Respirol, Tokyo, Japan
关键词
chemokine; idiopathic pulmonary arterial hypertension; inflammation; monocyte chemoattractant protein-1; vascular remodelling;
D O I
10.1111/j.1440-1843.2006.00821.x
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Objective: Monocyte chemoattractant protein-1 (MCP-1), a pro-inflammatory chemokine, has potent chemoattractant activity for monocytes/macrophages. We sought to investigate the clinical significance of MCP-1 in idiopathic pulmonary arterial hypertension (IPAH). Methods: This study included 28 patients with IPAH, seven patients with pulmonary arterial hypertension (PAH) related to collagen vascular disease, and 13 healthy subjects. Plasma MCP-1 levels were measured together with serum IL-6 and tumour necrosis factor-alpha (Tau Nu F-alpha) levels. Results: Circulating levels of MCP-1, IL-6 and Tau Nu F-alpha were significantly higher in patients with IPAH than in healthy controls, although they were lower than in patients with PAH related to collagen vascular disease. Plasma MCP-1 did not significantly correlate with any haemodynamic variables. However, plasma MCP-1 levels correlated negatively with the disease duration (time from symptom onset). Conclusions: Plasma MCP-1 levels were elevated in patients with IPAH, and this elevation was particularly marked in the early stage of disease. Taking into account the chemoattractant activity of MCP-1, these results imply a contribution of MCP-1 to the development of pulmonary hypertension.
引用
收藏
页码:158 / 163
页数:6
相关论文
共 31 条
[1]   Primary pulmonary hypertension - A vascular biology and translational research "work in progress" [J].
Archer, S ;
Rich, S .
CIRCULATION, 2000, 102 (22) :2781-2791
[2]   The role of chemokines in the pathogenesis of scleroderma [J].
Atamas, SP ;
White, B .
CURRENT OPINION IN RHEUMATOLOGY, 2003, 15 (06) :772-777
[3]   MONOCYTE CHEMOATTRACTANT PROTEIN-1 ACTS AS A T-LYMPHOCYTE CHEMOATTRACTANT [J].
CARR, MW ;
ROTH, SJ ;
LUTHER, E ;
ROSE, SS ;
SPRINGER, TA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :3652-3656
[4]  
Frade JMR, 1997, J IMMUNOL, V159, P5576
[5]   Costimulation of fibroblast collagen and transforming growth factor beta(1) gene expression by monocyte chemoattractant protein-1 via specific receptors [J].
GharaeeKermani, M ;
Denholm, EM ;
Phan, SH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (30) :17779-17784
[6]  
Gröndal G, 2000, CLIN EXP RHEUMATOL, V18, P565
[7]  
Hasegawa M, 1999, CLIN EXP IMMUNOL, V117, P159
[8]   Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension [J].
Hashimoto, K ;
Nakamura, K ;
Fujio, H ;
Miyaji, K ;
Morita, H ;
Kusano, K ;
Date, H ;
Shimizu, N ;
Emori, T ;
Matsubara, H ;
Ohe, T .
CIRCULATION JOURNAL, 2004, 68 (03) :227-231
[9]   Vascular remodeling in hypertension - Roles of apoptosis, inflammation, and fibrosis [J].
Intengan, HD ;
Schiffrin, EL .
HYPERTENSION, 2001, 38 (03) :581-587
[10]  
Kaneko H, 1999, J RHEUMATOL, V26, P568